In regards to CTHRC1, the first four compounds on the list were not well studied on cancer, while PF2341066, an inhibitor of anaplastic lymphoma kinase and c-Met later named as crizotinib, was previously shown to have antitumor activity of PF-2341066 in experimental models of anaplastic large-cell lymphoma. Here, MET is linked to anaplastic large cell lymphoma.